Posted on 22/01/2010 in Pharmaceutical Company Product News Ipsen and Inspiration Biopharmaceuticals have signed a contract which will see them collaborate to create a leading haemophilia franchise.
The partnership will cover the world's major haemophilia markets and will aim to leverage combined expertise and resources to develop a broad portfolio of recombinant proteins.
Together, the organisations will venture to address all major haemophilia disorders by concentrating on two major unmet needs - treatment for inhibitor complications and wider access to therapies with coagulation factors.
At present, two compounds are being trialled - Inspiration's IB1001 and Ipsen's OBI-1, which is intended to treat patients with acquired haemophilia and haemophilia A.
Jean-Luc Belingard, chairman and chief executive officer of Ipsen, commented: "Subject to the products in development being approved [...] and upon successful commercialisation, we believe Inspiration's portfolio, including OBI-1, could exceed sales of $1 billion (616.4 million pounds) in the next ten years."
Earlier this week, Ipsen and Roche revealed that Taspoglutide (R1583), a compound that they have been jointly working on, met its primary endpoints during two phase III trials. Other news stories from 22/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
